Northwest Biotherapeutics, Inc. (NWBO)

OTCMKTS: NWBO · Delayed Price · USD
0.855
+0.095 (12.50%)
Dec 1, 2023, 4:00 PM EST - Market closed
Market Cap 986.54M
Revenue (ttm) 2.08M
Net Income (ttm) -80.54M
Shares Out 1.15B
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,417,350
Open 0.770
Previous Close 0.760
Day's Range 0.725 - 0.880
52-Week Range 0.400 - 1.120
Beta -0.29
Analysts n/a
Price Target n/a
Earnings Date Feb 28, 2023

About NWBO

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 22
Stock Exchange OTCMKTS
Ticker Symbol NWBO
Full Company Profile

Financial Performance

Financial Statements

News

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

BETHESDA, Md. , Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...

11 days ago - PRNewsWire

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

BETHESDA, Md. , Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...

7 weeks ago - PRNewsWire

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

BETHESDA, Md. , Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, anno...

2 months ago - PRNewsWire

Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application

BETHESDA, Md. , Aug. 29, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, annou...

3 months ago - PRNewsWire

Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products; Allows Global Delivery of the Products BETHESDA, Md., March 20, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQ...

9 months ago - PRNewsWire

Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB

BETHESDA, Md. , March 11, 2023 /PRNewswire/ --  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, tod...

9 months ago - PRNewsWire

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

78% Of All Shares Were Voted; Proposals Received ≥90% of Votes Cast BETHESDA, Md. , Jan. 6, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing ...

11 months ago - PRNewsWire

Biotech Company Says Citadel, Other Big Traders Manipulated Its Stock Price

In a new lawsuit, Northwest Biotherapeutics accused market makers of illicit “spoofing” trades.

1 year ago - WSJ

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

Both Median Survival and "Long Tail" of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results Featured In JAMA Oncology Peer Reviewed Publication    BETHESDA, Md....

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA

PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients BETHESDA, Md. , Aug. 23, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a bi...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility

Application Package Developed By Advent BioServices; Builds on Licenses Obtained in 2021 BETHESDA, Md. , July 6, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnolog...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program

BETHESDA, Md. , June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, report...

1 year ago - PRNewsWire

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

BETHESDA, Md. , May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, report...

1 year ago - PRNewsWire

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

BETHESDA, Md. , May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reporte...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

BETHESDA, Md., Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

BETHESDA, Md., Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...

2 years ago - PRNewsWire

Northwest Biotherapeutics Announces $15 Million Financing

BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...

2 years ago - PRNewsWire

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...

2 years ago - PRNewsWire

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...

2 years ago - PRNewsWire

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today...

2 years ago - PRNewsWire